Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Ramy Younes; Olivier Govaere; Salvatore Petta; Luca Miele; Dina Tiniakos; Alastair Burt; Ezio David; Fabio Maria Vecchio; Marco Maggioni; Daniela Cabibi; Anna L. Fracanzani; Chiara Rosso; Maria J. Garcia Blanco; Angelo Armandi; Gian Paolo Caviglia; Marco Y. W. Zaki; Antonio Liguori; Paolo Francione; Grazia Pennisi; Antonio Grieco; Luca Valenti; Quentin M. Anstee; Elisabetta Bugianesi

doi:10.14309/ajg.0000000000000676

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Ramy Younes, Olivier Govaere, Salvatore Petta, Luca Miele, Dina Tiniakos, Alastair Burt, Ezio David, Fabio Maria Vecchio, Marco Maggioni, Daniela Cabibi, Anna L. Fracanzani, Chiara Rosso, Maria J. Garcia Blanco, Angelo Armandi, Gian Paolo Caviglia, Marco Y. W. Zaki, Antonio Liguori, Paolo Francione, Grazia Pennisi, Antonio GriecoLuca Valenti, Quentin M. Anstee, Elisabetta Bugianesi

Research output: Contribution to journal › Article

Abstract

INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

Original language	English
Pages (from-to)	1289-1292
Number of pages	4
Journal	THE AMERICAN JOURNAL OF GASTROENTEROLOGY
Volume	115
DOIs	https://doi.org/10.14309/ajg.0000000000000676
Publication status	Published - 2020

Keywords

n/a

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.14309/ajg.0000000000000676

Cite this

Younes, R., Govaere, O., Petta, S., Miele, L., Tiniakos, D., Burt, A., David, E., Vecchio, F. M., Maggioni, M., Cabibi, D., Fracanzani, A. L., Rosso, C., Blanco, M. J. G., Armandi, A., Caviglia, G. P., Zaki, M. Y. W., Liguori, A., Francione, P., Pennisi, G., ... Bugianesi, E. (2020). Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 115, 1289-1292. https://doi.org/10.14309/ajg.0000000000000676

@article{aa611e86ac4146de8997fe9ffe504073,

title = "Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease",

abstract = "INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.",

keywords = "n/a, n/a",

author = "Ramy Younes and Olivier Govaere and Salvatore Petta and Luca Miele and Dina Tiniakos and Alastair Burt and Ezio David and Vecchio, {Fabio Maria} and Marco Maggioni and Daniela Cabibi and Fracanzani, {Anna L.} and Chiara Rosso and Blanco, {Maria J. Garcia} and Angelo Armandi and Caviglia, {Gian Paolo} and Zaki, {Marco Y. W.} and Antonio Liguori and Paolo Francione and Grazia Pennisi and Antonio Grieco and Luca Valenti and Anstee, {Quentin M.} and Elisabetta Bugianesi",

year = "2020",

doi = "10.14309/ajg.0000000000000676",

language = "English",

volume = "115",

pages = "1289--1292",

journal = "THE AMERICAN JOURNAL OF GASTROENTEROLOGY",

issn = "1572-0241",

publisher = "New York: Elsevier Science",

}

Younes, R, Govaere, O, Petta, S, Miele, L, Tiniakos, D, Burt, A, David, E, Vecchio, FM, Maggioni, M, Cabibi, D, Fracanzani, AL, Rosso, C, Blanco, MJG, Armandi, A, Caviglia, GP, Zaki, MYW, Liguori, A, Francione, P, Pennisi, G, Grieco, A, Valenti, L, Anstee, QM & Bugianesi, E 2020, 'Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease', THE AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 115, pp. 1289-1292. https://doi.org/10.14309/ajg.0000000000000676

TY - JOUR

T1 - Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

AU - Younes, Ramy

AU - Govaere, Olivier

AU - Petta, Salvatore

AU - Miele, Luca

AU - Tiniakos, Dina

AU - Burt, Alastair

AU - David, Ezio

AU - Vecchio, Fabio Maria

AU - Maggioni, Marco

AU - Cabibi, Daniela

AU - Fracanzani, Anna L.

AU - Rosso, Chiara

AU - Blanco, Maria J. Garcia

AU - Armandi, Angelo

AU - Caviglia, Gian Paolo

AU - Zaki, Marco Y. W.

AU - Liguori, Antonio

AU - Francione, Paolo

AU - Pennisi, Grazia

AU - Grieco, Antonio

AU - Valenti, Luca

AU - Anstee, Quentin M.

AU - Bugianesi, Elisabetta

PY - 2020

Y1 - 2020

N2 - INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

AB - INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.

KW - n/a

UR - http://hdl.handle.net/10807/219759

U2 - 10.14309/ajg.0000000000000676

DO - 10.14309/ajg.0000000000000676

M3 - Article

SN - 1572-0241

VL - 115

SP - 1289

EP - 1292

JO - THE AMERICAN JOURNAL OF GASTROENTEROLOGY

JF - THE AMERICAN JOURNAL OF GASTROENTEROLOGY

ER -

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this